{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:51:51Z","timestamp":1767858711255,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.ygyno.2011.11.021","type":"journal-article","created":{"date-parts":[[2011,11,22]],"date-time":"2011-11-22T09:31:04Z","timestamp":1321954264000},"page":"42-47","source":"Crossref","is-referenced-by-count":78,"title":["A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites"],"prefix":"10.1016","volume":"125","clinical-trial-number":[{"clinical-trial-number":"nct00396591","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nicoletta","family":"Colombo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Mangili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serafina","family":"Mammoliti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e5rten","family":"Kalling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Tholander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Sternas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giliane","family":"Buzenet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.11.021_bb0005","first-page":"5721","article-title":"Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model","volume":"9","author":"Byrne","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0010","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.1158\/1078-0432.CCR-05-0910","article-title":"Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model","volume":"11","author":"Hu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0015","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7","article-title":"Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease","volume":"85","author":"Kraft","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0020","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.febslet.2006.03.087","article-title":"Biology of vascular endothelial growth factors","volume":"580","author":"Roy","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0025","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10434-999-0373-0","article-title":"Markedly elevated levels of vascular endothelial growth factor in malignant ascites","volume":"6","author":"Zebrowski","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0030","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0035","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1158\/1078-0432.CCR-06-2553","article-title":"Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model","volume":"13","author":"Verheul","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0040","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1073\/pnas.1432908100","article-title":"Regression of established tumors and metastases by potent vascular endothelial growth factor blockade","volume":"100","author":"Huang","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0045","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/JTO.0b013e3181e2f7fb","article-title":"A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung","volume":"5","author":"Leighl","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.2009.22.9237","article-title":"Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors","volume":"28","author":"Lockhart","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0140","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1200\/jco.2008.26.15_suppl.4027","article-title":"Phase II trial of aflibercept (VEGF-Trap) in previously treated patients with metastatic colorectal cancer (MCRC): a PMH phase II consortium trial","volume":"26","author":"Tang","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0145","doi-asserted-by":"crossref","first-page":"9028","DOI":"10.1200\/jco.2009.27.15_suppl.9028","article-title":"Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin","volume":"25","author":"Tarhini","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0065","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/1078-0432.CCR-09-2103","article-title":"Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors","volume":"16","author":"Tew","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0150","series-title":"16th International Meeting of the European Society of Gynaecological Oncology, Belgrade, Serbia, Oct 11\u201314, 2009","article-title":"Aflibercept (VEGF Trap) in advanced ovarian cancer patients with recurrent symptomatic malignant ascites: results of a randomized, double-blind, placebo-controlled study","author":"Vergote","year":"2009"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0080","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","article-title":"Malignant ascites: systematic review and guideline for treatment","volume":"42","author":"Becker","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0085","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ctrv.2010.03.001","article-title":"Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM\u00d7anti-CD3) as a targeted cancer immunotherapy","volume":"36","author":"Seimetz","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0090","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","article-title":"Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I\/II study","volume":"13","author":"Burges","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0095","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ygyno.2008.04.028","article-title":"Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer","volume":"111","author":"Hamilton","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0100","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2006.05.018","article-title":"The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma","volume":"102","author":"Numnum","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0105","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdl143","article-title":"Bevacizumab is active in malignant effusion","volume":"17","author":"Pichelmayer","year":"2006","journal-title":"Ann Oncol"},{"issue":"18S","key":"10.1016\/j.ygyno.2011.11.021_bb0155","article-title":"Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites","volume":"25","author":"El-Shami","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0115","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1634\/theoncologist.2009-0109","article-title":"Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?","volume":"14","author":"Kobold","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0120","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ygyno.2009.11.017","article-title":"Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma","volume":"116","author":"Diaz","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0125","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2007.06.004","article-title":"Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening","volume":"107","author":"Simpkins","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.021_bb0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ygyno.2010.01.011","article-title":"Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?","volume":"118","author":"Richardson","year":"2010","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811009395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811009395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T15:53:47Z","timestamp":1639756427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811009395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0090825811009395"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.11.021","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}